Search Results - "Liguori, Rebecca"

Ipilimumab for Patients with Relapse after Allogeneic Transplantation by Davids, Matthew S, Kim, Haesook T, Bachireddy, Pavan, Costello, Caitlin, Liguori, Rebecca, Savell, Alexandra, Lukez, Alexander P, Avigan, David, Chen, Yi-Bin, McSweeney, Peter, LeBoeuf, Nicole R, Rooney, Michael S, Bowden, Michaela, Zhou, Chensheng W, Granter, Scott R, Hornick, Jason L, Rodig, Scott J, Hirakawa, Masahiro, Severgnini, Mariano, Hodi, F. Stephen, Wu, Catherine J, Ho, Vincent T, Cutler, Corey, Koreth, John, Alyea, Edwin P, Antin, Joseph H, Armand, Philippe, Streicher, Howard, Ball, Edward D, Ritz, Jerome, Bashey, Asad, Soiffer, Robert J

“…Hematologic cancers that recur after allogeneic hematopoietic stem-cell transplantation are often difficult to treat. A small pilot study suggests that…”
Get full text

A Multicenter Phase I Study of CTLA-4 Blockade with Ipilimumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation by Davids, Matthew S., Kim, Haesook T., Costello, Caitlin L., Avigan, David, Chen, Yi-Bin, Armand, Philippe, Alyea, Edwin P., Hedlund, Jacquelyn, McSweeney, Peter A., Liguori, Rebecca, Ritz, Jerome, Ball, Edward D., Bashey, Asad, Soiffer, Robert J

“…The prognosis for patients with hematologic malignancies (HM) who relapse after allo-HCT is dismal, and more effective treatments are urgently needed. Immune…”
Get full text

A Multicenter Phase I/Ib Study of Ipilimumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation by Davids, Matthew S., Kim, Haesook T., Costello, Caitlin L., McSweeney, Peter A., Liguori, Rebecca, Lukez, Alexander, Avigan, David, Chen, Yi-Bin, LeBoeuf, Nicole, Ho, Vincent T., Cutler, Corey S, Koreth, John, Alyea, Edwin P., Antin, Joseph H, Ritz, Jerome, Armand, Philippe, Ball, Edward D, Bashey, Asad, Soiffer, Robert J.

“…▪ The prognosis for patients (pts) with hematologic malignancies (HM) who relapse after alloHSCT is dismal, and novel treatment options are urgently needed…”
Get full text

A Phase 1/2 Trial of TH-302 and Dexamethasone without or with Bortezomib (TBorD) in Patients with Relapsed/Refractory Multiple Myeloma by Laubach, Jacob P., Raje, Noopur S., Yee, Andrew J., Armand, Philippe, Schlossman, Robert L., Rosenblatt, Jacalyn, Matous, Jeffrey, Hedlund, Jacquelyn, Martin, Michael G, Reynolds, Craig, Shain, Kenneth H., Zackon, Ira, Stampleman, Laura V., Boswell, Erica N, Chuma, Stacey, Liguori, Rebecca, Mar, Stephanie, Handisides, Damian, Kroll, Stew, Anderson, Kenneth C., Richardson, Paul G., Ghobrial, Irene M.

“…Background: TH-302 is a 2-nitroimidazole prodrug of the DNA alkylator bromo-isophosphoramide mustard that is selectively activated under hypoxic conditions…”
Get full text

Preliminary safety and efficacy of TH-302, an investigational hypoxia-targeted drug, and dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RR MM) by Laubach, Jacob, Raje, Noopur S., Armand, Philippe, Schlossman, Robert L., Rosenblatt, Jacalyn, Matous, Jeffrey, Hedlund, Jacquelyn Ann, Martin, Michael Gary, Reynolds, Craig H., Shain, Kenneth H., Zackon, Ira, Stampleman, Laura, Boswell, Erica, Chuma, Stacey, Liguori, Rebecca, Handisides, Damian, Kroll, Stew, Anderson, Kenneth Carl, Richardson, Paul G., Ghobrial, Irene M.

“…Abstract only…”
Get full text

Preliminary safety and efficacy of evofosfamide (TH-302), an investigational hypoxia-activated prodrug, combined with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma (RR MM) by Laubach, Jacob, Raje, Noopur S., Yee, Andrew Jenho, Armand, Philippe, Schlossman, Robert L., Rosenblatt, Jacalyn, Hedlund, Jacquelyn Ann, Martin, Michael Gary, Reynolds, Craig H., Shain, Kenneth H., Zackon, Ira, Stampleman, Laura, Boswell, Erica, Chuma, Stacey, Liguori, Rebecca, Handisides, Damian, Kroll, Stew, Anderson, Kenneth Carl, Richardson, Paul G., Ghobrial, Irene M.

“…Abstract only…”
Get full text